Ziprasidone ameliorates anxiety-like behaviors in a rat model of PTSD and up-regulates neurogenesis in the hippocampus and hippocampus-derived neural stem cells

Behavioural Brain Research

Volumn 244, Issue , 2013, Pages 1-8

  Peng, Zhengwu ^a   Zhang, Ruiguo ^a   Wang, Huaning ^a   Chen, Yunchun ^a   Xue, Fen ^a   Wang, Lei ^a   Yang, Fan ^a   Chen, Yihuan ^a   Liu, Ling ^b   Kuang, Fang ^b   Tan, Qingrong ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Hippocampus; Neural stem cells; Neurogenesis; Post traumatic stress disorder; Ziprasidone

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN BCL 2; UNCLASSIFIED DRUG; Z 2777; ZIPRASIDONE;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; BRAIN REGION; CELL LEVEL; CELL PROLIFERATION; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFICACY; DRUG MECHANISM; EMBRYO; FETUS; HIPPOCAMPUS; IN VITRO STUDY; IN VIVO STUDY; MALE; MENTAL STRESS; NERVOUS SYSTEM DEVELOPMENT; NEURAL STEM CELL; NONHUMAN; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; UPREGULATION;

ANIMALS; ANTI-ANXIETY AGENTS; BUTADIENES; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; HIPPOCAMPUS; MALE; MAP KINASE SIGNALING SYSTEM; NEURAL STEM CELLS; NEUROGENESIS; NITRILES; PIPERAZINES; PROTEIN KINASE INHIBITORS; RATS; STRESS DISORDERS, POST-TRAUMATIC; THIAZOLES; UP-REGULATION;

EID: 84874358720     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2013.01.032     Document Type: Article

References (59)

1. Berger W., Figueira I., Maurat A.M., Bucassio E.P., Vieira I., Jardim S.R., et al. Partial and full PTSD in Brazilian ambulance workers: prevalence and impact on health and on quality of life. Journal of Traumatic Stress 2007, 20:637-642.
2. Clapp J.D., Beck J.G., Palyo S.A., Grant D.M. An examination of the synergy of pain and PTSD on quality of life: additive or multiplicative effects. Pain 2008, 138:301-309.
3. Warshaw M.G., Fierman E., Pratt L., Hunt M., Yonkers K.A., Massion A.O., et al. Quality of life and dissociation in anxiety disorder patients with histories of trauma or PTSD. American Journal of Psychiatry 1993, 150:1512-1516.
4. Ma X., Liu X., Hu X., Qiu C., Wang Y., Huang Y., et al. Risk indicators for post-traumatic stress disorder in adolescents exposed to the 5.12 Wenchuan earthquake in China. Psychiatry Research 2011, 189:385-391.
5. Maes M., Delmeire L., Mylle J., Altamura C. Risk and preventive factors of post-traumatic stress disorder (PTSD): alcohol consumption and intoxication prior to a traumatic event diminishes the relative risk to develop PTSD in response to that trauma. Journal of Affective Disorders 2001, 63:113-121.
6. Mak I.W., Chu C.M., Pan P.C., Yiu M.G., Ho S.C., Chan V.L. Risk factors for chronic post-traumatic stress disorder (PTSD) in SARS survivors. General Hospital Psychiatry 2010, 32:590-598.
7. Trickey D., Siddaway A.P., Meiser-Stedman R., Serpell L., Field A.P. A meta-analysis of risk factors for post-traumatic stress disorder in children and adolescents. Clinical Psychology Review 2012, 32:122-138.
8. Kitayama N., Vaccarino V., Kutner M., Weiss P., Bremner J.D. Magnetic resonance imaging (MRI) measurement of hippocampal volume in posttraumatic stress disorder: a meta-analysis. Journal of Affective Disorders 2005, 88:79-86.
9. Lindauer R.J., Olff M., van Meijel E.P., Carlier I.V., Gersons B.P. Cortisol, learning, memory, and attention in relation to smaller hippocampal volume in police officers with posttraumatic stress disorder. Biological Psychiatry 2006, 59:171-177.
10. Bremner J.D., Elzinga B., Schmahl C., Vermetten E. Structural and functional plasticity of the human brain in posttraumatic stress disorder. Progress in Brain Research 2008, 167:171-186.
11. Hendriksen H., Prins J., Olivier B., Oosting R.S. Environmental enrichment induces behavioral recovery and enhanced hippocampal cell proliferation in an antidepressant-resistant animal model for PTSD. PLoS One 2010, 5:e11943.
12. Kikuchi A., Shimizu K., Nibuya M., Hiramoto T., Kanda Y., Tanaka T., et al. Relationship between post-traumatic stress disorder-like behavior and reduction of hippocampal 5-bromo-2'-deoxyuridine-positive cells after inescapable shock in rats. Psychiatry and Clinical Neurosciences 2008, 62:713-720.
13. Li X., Han F., Liu D., Shi Y. Changes of Bax, Bcl-2 and apoptosis in hippocampus in the rat model of post-traumatic stress disorder. Neurology Research 2010, 32:579-586.
14. Li X.M., Han F., Liu D.J., Shi Y.X. Single-prolonged stress induced mitochondrial-dependent apoptosis in hippocampus in the rat model of post-traumatic stress disorder. Journal of Chemical Neuroanatomy 2010, 40:248-255.
15. Kim J.J., Lee H.J., Welday A.C., Song E., Cho J., Sharp P.E., et al. Stress-induced alterations in hippocampal plasticity, place cells, and spatial memory. Proceedings of the National Academy of Sciences USA 2007, 104:18297-18302.
16. Yang J., Hou C., Ma N., Liu J., Zhang Y., Zhou J., et al. Enriched environment treatment restores impaired hippocampal synaptic plasticity and cognitive deficits induced by prenatal chronic stress. Neurobiology of Learning and Memory 2007, 87:257-263.
17. Rosenbrock H., Koros E., Bloching A., Podhorna J., Borsini F. Effect of chronic intermittent restraint stress on hippocampal expression of marker proteins for synaptic plasticity and progenitor cell proliferation in rats. Brain Research 2005, 1040:55-63.
18. Acheson D.T., Gresack J.E., Risbrough V.B. Hippocampal dysfunction effects on context memory: possible etiology for posttraumatic stress disorder. Neuropharmacology 2012, 62:674-685.
19. Bremner J.D., Vermetten E. Neuroanatomical changes associated with pharmacotherapy in posttraumatic stress disorder. Annals of the New York Academy of Sciences 2004, 1032:154-157.
20. Vermetten E., Vythilingam M., Southwick S.M., Charney D.S., Bremner J.D. Long-term treatment with paroxetine increases verbal declarative memory and hippocampal volume in posttraumatic stress disorder. Biological Psychiatry 2003, 54:693-702.
21. Nemeroff C.B., Lieberman J.A., Weiden P.J., Harvey P.D., Newcomer J.W., Schatzberg A.F., et al. From clinical research to clinical practice: a 4-year review of ziprasidone. CNS Spectrums 2005, 10:1-20.
22. Schmidt A.W., Lebel L.A., Howard H.R., Zorn S.H. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. European Journal of Pharmacology 2001, 425:197-201.
23. Kam K.Y., Jalin A.M., Choi Y.W., Kaengkan P., Park S.W., Kim Y.H., et al. Ziprasidone attenuates brain injury after focal cerebral ischemia induced by middle cerebral artery occlusion in rats. Prog Neuropsychopharmacol Biol Psychiatry 2012, 39:69-74.
24. Cosi C., Waget A., Rollet K., Tesori V., Newman-Tancredi A. Clozapine, ziprasidone and aripiprazole but not haloperidol protect against kainic acid-induced lesion of the striatum in mice, in vivo: role of 5-HT1A receptor activation. Brain Research 2005, 1043:32-41.
25. Park S.W., Lee C.H., Lee J.G., Lee S.J., Kim N.R., Choi S.M., et al. Differential effects of ziprasidone and haloperidol on immobilization stress-induced mRNA BDNF expression in the hippocampus and neocortex of rats. Journal of Psychiatric Research 2009, 43:274-281.
26. Benninghoff J., Grunze H., Schindler C., Genius J., Schloesser R.J., van der Ven A., et al. Ziprasidone - Not Haloperidol - Induces more de-novo Neurogenesis of Adult Neural Stem Cells Derived from Murine Hippocampus. Pharmacopsychiatry 2013, 46:10-15.
27. Frecska E., Keresztes M., Gaszner G. [Misdiagnosed PTSD and zeldox pharmacotherapy in case of a political prisoner]. Neuropsychopharmacologia Hungarica 2004, 6:221-223.
28. Siddiqui Z., Marcil W.A., Bhatia S.C., Ramaswamy S., Petty F. Ziprasidone therapy for post-traumatic stress disorder. Journal of Psychiatry & Neuroscience 2005, 30:430-431.
29. Wang H.N., Peng Y., Tan Q.R., Chen Y.C., Zhang R.G., Qiao Y.T., et al. Quetiapine ameliorates anxiety-like behavior and cognitive impairments in stressed rats: implications for the treatment of posttraumatic stress disorder. Physiological Research 2010, 59:263-271.
30. Abdul-Monim Z., Reynolds G.P., Neill J.C. The effect of atypical and classical antipsychotics on sub-chronic PCP-induced cognitive deficits in a reversal-learning paradigm. Behavioural Brain Research 2006, 169:263-273.
31. Du J., Wang Q., Hu B., Peng Z., Zhao Y., Ma L., et al. Involvement of ERK 1/2 activation in electroacupuncture pretreatment via cannabinoid CB1 receptor in rats. Brain Research 2010, 1360:1-7.
32. Sironi L., Banfi C., Brioschi M., Gelosa P., Guerrini U., Nobili E., et al. Activation of NF-kB and ERK1/2 after permanent focal ischemia is abolished by simvastatin treatment. Neurobiology of Disease 2006, 22:445-451.
33. Wang H.N., Peng Y., Tan Q.R., Wang H.H., Chen Y.C., Zhang R.G., et al. Free and Easy Wanderer Plus (FEWP), a polyherbal preparation, ameliorates PTSD-like behavior and cognitive impairments in stressed rats. Progress in Neuropsychopharmacology and Biological Psychiatry 2009, 33:1458-1463.
34. Wang W., Liu Y., Zheng H., Wang H.N., Jin X., Chen Y.C., et al. A modified single-prolonged stress model for post-traumatic stress disorder. Neuroscience Letters 2008, 441:237-241.
35. Cunha J.M., Masur J. Evaluation of psychotropic drugs with a modified open field test. Pharmacology 1978, 16:259-267.
36. Libert S., Pointer K., Bell E.L., Das A., Cohen D.E., Asara J.M., et al. SIRT1 activates MAO-A in the brain to mediate anxiety and exploratory drive. Cell 2011, 147:1459-1472.
37. Peng Z.W., Xue Y.Y., Wang H.N., Wang H.H., Xue F., Kuang F., et al. Sertraline promotes hippocampus-derived neural stem cells differentiating into neurons but not glia and attenuates LPS-induced cellular damage. Progress in Neuropsychopharmacology Biology and Psychiatry 2012, 36:183-188.
38. Bauer M.S., Altshuler L., Evans D.R., Beresford T., Williford W.O., Hauger R. Prevalence and distinct correlates of anxiety, substance, and combined comorbidity in a multi-site public sector sample with bipolar disorder. Journal of Affective Disorders 2005, 85:301-315.
39. Nemeroff C.B., Bremner J.D., Foa E.B., Mayberg H.S., North C.S., Stein M.B. Posttraumatic stress disorder: a state-of-the-science review. Journal of Psychiatric Research 2006, 40:1-21.
40. Schneier F.R., Neria Y., Pavlicova M., Hembree E., Suh E.J., Amsel L., et al. Combined prolonged exposure therapy and paroxetine for PTSD related to the World Trade Center attack: a randomized controlled trial. American Journal of Psychiatry 2012, 169:80-88.
41. Corchs F., Nutt D.J., Hood S., Bernik M. Serotonin and sensitivity to trauma-related exposure in selective serotonin reuptake inhibitors-recovered posttraumatic stress disorder. Biological Psychiatry 2009, 66:17-24.
42. Berger W., Mendlowicz M.V., Marques-Portella C., Kinrys G., Fontenelle L.F., Marmar C.R., et al. Pharmacologic alternatives to antidepressants in posttraumatic stress disorder: a systematic review. Progress in Neuropsychopharmacology & Biological Psychiatry 2009, 33:169-180.
43. Stein M.B., Kline N.A., Matloff J.L. Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study. Am Journal of Psychiatry 2002, 159:1777-1779.
44. Zohar J., Amital D., Miodownik C., Kotler M., Bleich A., Lane R.M., et al. Double-blind placebo-controlled pilot study of sertraline in military veterans with posttraumatic stress disorder. Journal of Clinical Psychopharmacology 2002, 22:190-195.
45. Davidson J.R. Pharmacologic treatment of acute and chronic stress following trauma: 2006. Journal of Clinical Psychiatry 2006, 67(Suppl. 2):34-39.
46. Bartzokis G., Lu P.H., Turner J., Mintz J., Saunders C.S. Adjunctive risperidone in the treatment of chronic combat-related posttraumatic stress disorder. Biological Psychiatry 2005, 57:474-479.
47. Ahearn E.P., Mussey M., Johnson C., Krohn A., Krahn D. Quetiapine as an adjunctive treatment for post-traumatic stress disorder: an 8-week open-label study. International Clinical Psychopharmacology 2006, 21:29-33.
48. Pivac N., Kozaric-Kovacic D., Muck-Seler D. Olanzapine versus fluphenazine in an open trial in patients with psychotic combat-related post-traumatic stress disorder. Psychopharmacology (Berl) 2004, 175:451-456.
49. Davis L.L., Frazier E.C., Williford R.B., Newell J.M. Long-term pharmacotherapy for post-traumatic stress disorder. CNS Drugs 2006, 20:465-476.
50. Kozaric-Kovacic D., Pivac N. Quetiapine treatment in an open trial in combat-related post-traumatic stress disorder with psychotic features. International Journal of Neuropsychopharmacology 2007, 10:253-261.
51. Einat H., Yuan P., Gould T.D., Li J., Du J., Zhang L., et al. The role of the extracellular signal-regulated kinase signaling pathway in mood modulation. Journal of Neuroscience 2003, 23:7311-7316.
52. Mercier G., Lennon A.M., Renouf B., Dessouroux A., Ramauge M., Courtin F., et al. MAP kinase activation by fluoxetine and its relation to gene expression in cultured rat astrocytes. Journal of Molecular Neuroscience 2004, 24:207-216.
53. Hayley S., Poulter M.O., Merali Z., Anisman H. The pathogenesis of clinical depression: stressor- and cytokine-induced alterations of neuroplasticity. Neuroscience 2005, 135:659-678.
54. Xiao Z., Kong Y., Yang S., Li M., Wen J., Li L. Upregulation of Flk-1 by bFGF via the ERK pathway is essential for VEGF-mediated promotion of neural stem cell proliferation. Cell Research 2007, 17:73-79.
55. Chiou S.H., Ku H.H., Tsai T.H., Lin H.L., Chen L.H., Chien C.S., et al. Moclobemide upregulated Bcl-2 expression and induced neural stem cell differentiation into serotoninergic neuron via extracellular-regulated kinase pathway. British Journal of Pharmacology 2006, 148:587-598.
56. Moors M., Cline J.E., Abel J., Fritsche E. ERK-dependent and -independent pathways trigger human neural progenitor cell migration. Toxicology and Applied Pharmacology 2007, 221:57-67.
57. Manakova S., Puttonen K.A., Raasmaja A., Mannisto P.T. The roles of dopamine transporter and Bcl-2 protein in the protection of CV1-P cells from 6-OHDA-induced toxicity. Toxicology Letters 2004, 154:117-123.
58. Hunsberger J.G., Austin D.R., Chen G., Manji H.K. Cellular mechanisms underlying affective resiliency: the role of glucocorticoid receptor- and mitochondrially-mediated plasticity. Brain Research 2009, 1293:76-84.
59. McEwen B.S., Gould E.A., Sakai R.R. The vulnerability of the hippocampus to protective and destructive effects of glucocorticoids in relation to stress. British Journal of Psychiatry Suppl. 1992, 1:8-23.